Belantamab Mafodotin: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Belantamab Mafodotin. Educational only — not medical advice.

Labeled uses

BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.

Source: FDA labeling via NIH DailyMed (set aef7c34c…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.